Description
Nexome Capital Markets Limited has fixed March 5, 2026 as the record date for its rights issue, offering 1 equity share for every 2 held at Rs 75/- per share (Rs 10 face value + Rs 65 premium). Trading in equity shares will be on an ex-rights basis from the same date.
Summary
BSE has notified trading members that Nexome Capital Markets Limited (Scrip Code: 508905) has fixed March 5, 2026 as the record date for its rights issue of equity shares. All transactions in the company’s equity shares must be conducted on an ex-rights basis with effect from that date under Settlement No. DR-833/2025-2026.
Key Points
- Company: Nexome Capital Markets Limited (BSE Code: 508905)
- Rights Ratio: 1 (one) new equity share for every 2 (two) equity shares held
- Issue Price: Rs 75/- per share (face value Rs 10/- + premium Rs 65/-)
- Record Date: March 5, 2026
- Ex-Rights Date: March 5, 2026 (DR-833/2025-2026)
- Segment: Dematerialised Securities – Rolling Settlement Segment
Regulatory Changes
No new regulatory changes. This is a standard corporate action notification pursuant to BSE listing compliance requirements for rights issues.
Compliance Requirements
- Trading members must ensure all transactions in Nexome Capital Markets Limited equity shares (Scrip Code: 508905) are executed on an ex-rights basis effective March 5, 2026.
- Members should update their systems to reflect the ex-rights adjustment from the specified settlement date (DR-833/2025-2026).
Important Dates
| Event | Date |
|---|---|
| Notice Date | February 27, 2026 |
| Record Date | March 5, 2026 |
| Ex-Rights Basis Effective From | March 5, 2026 |
| Settlement Number | DR-833/2025-2026 |
Impact Assessment
This rights issue has a medium market impact, limited to existing shareholders of Nexome Capital Markets Limited. Eligible shareholders as of the record date (March 5, 2026) will be entitled to subscribe to 1 new share for every 2 held at Rs 75/- per share. Trading members must account for the ex-rights price adjustment from March 5, 2026 onward. The rights ratio (1:2) and premium pricing (Rs 65/-) are standard; no broader market or systemic impact is anticipated.
Impact Justification
Routine rights issue corporate action affecting existing shareholders of a single SME-segment company; trading members must transact on ex-rights basis from the record date.